Waxman To Seek Consensus On FOBs, Incentives For Early Patent Resolution
Executive Summary
Efforts will be made "over the next few months" to bring House Energy and Commerce Committee members to a consensus on a follow-on biologics bill, according to committee staffer Ann Witt
You may also be interested in...
Will Waxman Offer Seven Years Of Exclusivity For Follow-On Biologics?
Revised bill is expected shortly as Reps. Eshoo and Barton draw battle line against the Commerce Committee chairman.
BLA Exclusivity Would Ease Acquisitions And Improve R&D Focus, Lilly Says
Lilly has found another reason for follow-on biologics legislation to provide 14 years of data exclusivity for innovators: it will make the vetting process easier in mergers and acquisitions
Follow The Follow-On Money: Obama’s Budget Has Modest Biogeneric Savings
The fiscal 2010 federal budget outlined by the Obama administration Feb. 25 takes a conservative view of the fiscal benefit of generic biologics - estimating they will contribute $9.2 billion over 10 years to help pay for health care reform